MiiHealth AI Closes Seed Round for an Undisclosed Amount to Reinvent Patient Intake and Give Providers Back Two Hours a Day
MiiHealth AI Closes Seed Round for an Undisclosed Amount to Reinvent Patient Intake and Give Providers Back Two Hours a Day
The funding accelerates deployment of the first agentic medical assistant that autonomously calls patients before visits, captures structured clinical histories, and writes intake notes directly into the EHR, thereby reshaping how health systems approach the front door of care.
MiiHealth AI, maker of the first agentic AI medical assistant purpose-built to automate patient intake, today announced the closing of a seed funding round for an undisclosed amount led by Russell Glass, former CEO of Headspace and founder of Arteria Capital. The round includes participation from a select group of physician angels, healthcare operators, and digital health founders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825710918/en/

The MiiHealth AI team. MiiHealth AI is advancing agentic AI for healthcare through DAINA, one of its conversational medical assistants designed to conduct patient conversations on behalf of care teams. The company recently raised an undisclosed amount in seed funding to accelerate product development and expansion.
MiiHealth AI’s assistant, DAINA (Dynamic AI Intake and Navigation Agent), autonomously calls patients before their appointments, conducts a natural, multi-turn clinical intake interview in the patient’s preferred language, and writes a structured, clinician-ready note directly into the chart, all without requiring the provider to be present. By shifting intake work upstream and out of the exam room, DAINA prepares the chart before every visit and gives providers back more than two hours a day that would otherwise be spent on repetitive questioning and manual documentation. This additional capacity gives providers the flexibility to spend more time with each patient, as well as to undertake more billable activities.
“This raise fuels our next chapter: a more trustworthy clinical Agent, deeper roots across 70% of the country’s EHR landscape, and a market position that sets a new standard for what AI-driven care looks like,” said Kelvin Summoogum, founder and CEO of MiiHealth AI.
DAINA has already completed successful clinical validation in some of the most demanding environments in medicine. In a large cardiology deployment at Mayo Clinic, the assistant completed agentic intake across hundreds of patients, delivering measurable returns through significant provider time savings per encounter and exceptionally high levels of patient trust and comfort in sharing sensitive health information. Early results showed that patients found DAINA empathetic and easy to use. Providers were able to reclaim significant time from the intake process while maintaining clinical quality.
“MiiHealth AI automates patient intake, one of the most overlooked and painful parts of the clinical workflow,” said Russell Glass, Founder of Arteria Capital and former CEO of Headspace. “Without asking clinicians to change how they practice, MiiHealth saves more than 8 minutes per cardiology encounter at Mayo Clinic, and patients love it. This is the kind of easy-to-implement and scalable win-win that health systems are looking for.”
The MiiHealth AI platform, powered by DAINA and the underlying MediiFlow intake automation engine, includes:
- Autonomous outbound intake calls that use specialty-specific protocols to capture complete clinical histories and red flags before the visit.
- Multi-language, voice-based interviews that feel like a conversation rather than a form, improving access and patient engagement across diverse populations.
- Automatic generation of structured, EHR-ready intake notes mapped to the right clinical fields, giving providers a concise, actionable summary when they open the chart.
- An integration layer that delivers notes into leading EHRs via HL7v2 and other standards, with full auditability and enterprise-grade security.
Health systems and clinics use MiiHealth AI to reduce pre-visit administrative burden, increase throughput, and unlock more billable visit slots without adding staff, driving a clear return on investment while delivering a calmer, more personal and genuinely delightful patient journey and improving the quality of clinical information captured during intake.
The seed funding will be used to expand engineering and AI teams to broaden DAINA’s specialty protocol catalogue and deepen its clinical reasoning and safety checks, accelerate integrations with major EHRs and health system infrastructure, and grow commercial and customer success teams to support health systems, specialty practices, and virtual-first providers adopting automated intake across multiple departments.
“Intake has been a stubborn bottleneck in healthcare for decades,” added Kelvin Summoogum. “Our vision is that every patient gets a thoughtful, complete intake before they ever see their clinician, and every clinician starts their day with charts that are already prepared. This seed round allows us to scale that vision from several successful clinical validation projects into broad deployment across health systems.”
About MiiHealth AI
MiiHealth AI is a digital health company building DAINA, an agentic AI medical assistant that autonomously conducts pre-visit patient intake and follow-up. DAINA calls patients in their preferred language, captures structured clinical histories using specialty-specific protocols, and writes intake notes directly into the EHR, giving providers back hours each day and expanding care capacity without additional staff. MiiHealth AI partners with health systems, medical groups, and specialty clinics to reduce documentation burden, improve access, and elevate the experience of care for both providers and patients. To learn more, visit miihealth.ai.
Media Contact
MiiHealth AI
hello@miihealth.ai
miihealth.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20260825710918/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner